Investing.com - Kiniksa Pharma (NASDAQ: KNSA) reported first quarter EPS of $-0.25, $0.11 worse than the analyst estimate of $-0.14. Revenue for the quarter came in at $79.86M versus the consensus estimate of $76.97M.
Guidance
Kiniksa Pharma sees FY 2024 revenue of $370.00M-$390.00M versus the analyst consensus of $383.00M.
Kiniksa Pharma's stock price closed at $17.09. It is down -6.20% in the last 3 months and up 48.09% in the last 12 months.
Kiniksa Pharma saw positive EPS revisions and negative EPS revisions in the last 90 days. See Kiniksa Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Kiniksa Pharma's Financial Health score is "good performance".
Check out Kiniksa Pharma's recent earnings performance, and Kiniksa Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar